PAK1 and cancer: Nevertheless, the constant use of Rac inhibitors in cancer treatment could generate some off-target effects in platelets because of the indirect inhibition of p21-activated kinase 1/2 (PAK1/2) [126], thus the administration of those Rac inhibitors should be controlled and interrupted when these undesired effects arise.